
Liz Thomas and Caleb Silver discuss the impact of GLP-1 drugs on various markets and consumer behavior.
About one in eight U.S. adults say they take a GLP-1 drug, according to a poll by the Kaiser Family Foundation. And that raises a number of questions for investors. As use of drugs such as Ozempic, Wegovy and Zepbound grows, the effects are moving far beyond healthcare and into the way people eat, shop, and spend. In this episode of The Important Part, Liz Thomas sits down with Caleb Silver, editor-in-chief of Investopedia and Chief Business Editor at People Inc., to examine the rise of the “GLP-1 economy.” Together, they explore how changing consumer behavior could affect food companies, restaurants, apparel, travel, home appliances, telehealth, and the pharmaceutical industry. Liz and Caleb also discuss where new demand may emerge, which established businesses could face pressure, and what investors should watch as the GLP-1 market continues to develop. Can major brands adapt quickly enough, or will a new group of companies be built around this changing consumer? This episode is for informational purposes only and should not be considered investment or medical advice. For more, read Liz’s column every Thursday at On The Money by…
Host: Liz Thomas
Guest: Caleb Silver
Organizations: Investopedia, People Inc., Kaiser Family Foundation
Products: Ozempic, Wegovy, Zepbound
Explore listener stats, chart rankings, contacts and more on the The Important Part: Investing with Liz Thomas podcast page.